Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Correction: Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

Fig. 3

Ibrutinib induces autophagy in GBM cells. (a) TEM revealed autophagosome ultrastructures in the enlarged images (arrows) after a 24-h treatment with 10 µM ibrutinib. (b) Representative images of immunocytochemistry. Red fluorescence indicates the presence of LC-3 protein. (c, d) GBM cells were incubated with different concentrations of ibrutinib for 24 h (c) or with 10 µM ibrutinib for various times (d), and LC3A/B-II, Atg7, and GAPDH levels were assessed by immunoblotting. (e) LC3A/B and Atg7 levels examined by western blot analysis in LN229 and U87 cells after treatment with ibrutinib (10 µM) or DMSO, in the absence or presence of 3MA (2 nM)

Back to article page